ArticleScientific reports2024
Modulating the skin mycobiome-bacteriome and treating seborrheic dermatitis with a probiotic-enriched oily suspension.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Clinical Severity and Outcome Measures in Seborrheic Dermatitis: A Systematic Review.Dermatology and therapy · 2026Pooled it
- Probiotic effects on skin health: comprehensive visual analysis and perspectives.Frontiers in microbiology · 2024Pooled it
- Omics-based decoding of molecular and metabolic crosstalk in the skin barrier ecosystem.Cell death and differentiation · 2026Review
- Preliminary Characterization of Skin Microbiota and Mycobiota in Atopic Dermatitis by Metagenomic and Culture-Based Analyses.Life (Basel, Switzerland) · 2026Article
- The human skin microbiome: from metagenomes to therapeutics.Nature reviews. Microbiology · 2025Review
- Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies-A Narrative Review.Biomedicines · 2025Review
- Microbial Profiling of Buffalo Mozzarella Whey and Ricotta Exhausted Whey: Insights into Potential Probiotic Subdominant Strains.Microorganisms · 2025Article
- Microbiome-Based Products: Therapeutic Potential for Inflammatory Skin Diseases.International journal of molecular sciences · 2025Review
- Comparative Analysis of Bacteriome in Hair Follicle Layers of Patients with Female Pattern Androgenic Alopecia.Microorganisms · 2025Article
- Skin Barrier Dysfunction in Chronic Dermatoses: From Pathophysiology to Emerging Therapeutic Strategies.Cureus · 2025Review
- Evaluation of skin cancer prevention properties of probiotics.Genes & nutrition · 2025Review
- Influence of Probiotic Administration in Canine Feed: A Comprehensive Review.Veterinary sciences · 2025Review
- Seborrheic Dermatitis: Exploring the Complex Interplay withInternational journal of molecular sciences · 2025Review
- Role of immune cells in seborrheic dermatitis: a two-sample bidirectional Mendelian randomization study.Archives of dermatological research · 2025Article
- Skin Microbiota: Mediator of Interactions Between Metabolic Disorders and Cutaneous Health and Disease.Microorganisms · 2025Review
- Global and Regional Burden of Seborrheic Dermatitis: Trends in Incidence and DALYs, 1990-2021.Clinical, cosmetic and investigational dermatology · 2025Article
- Genomic characterization and antibiotic susceptibility of biofilm-formingFrontiers in cellular and infection microbiology · 2025Article
- Article
- Facial Skin Microbiome Composition and Functional Shift with Aging.Microorganisms · 2024Article
- Efficacy of sodium hypochlorite in overcoming antimicrobial resistance and eradicating biofilms in clinical pathogens from pressure ulcers.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seborrheic dermatitis (SD) affects 2-5% of the global population, with imbalances in the skin microbiome implicated in its development. This study assessed the impact of an oily suspension containing Lactobacillus crispatus P17631 and Lacticaseibacillus paracasei I1688 (termed EUTOPLAC) on SD symptoms and the skin mycobiome-bacteriome modulation. 25 SD patients were treated with EUTOPLAC for a week. Symptom severity and skin mycobiome-bacteriome changes were measured at the start of the treatment (T0), after seven days (T8), and three weeks post-treatment (T28). Results indicated symptom improvement post-EUTOPLAC, with notable reductions in the Malassezia genus. Concurrently, bacterial shifts were observed, including a decrease in Staphylococcus and an increase in Lactobacillus and Lacticaseibacillus. Network analysis highlighted post-EUTOPLAC instability in fungal and bacterial interactions, with increased negative correlations between Malassezia and Lactobacillus and Lacticaseibacillus genera. The study suggests EUTOPLAC's potential as a targeted SD treatment, reducing symptoms and modulating the mycobiome-bacteriome composition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.